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The major aim of the contemporary endocrine therapy of breast cancer is to reduce oestrogen
.stimulation of tumour cell proliferation. This can be achieved by one of two mechanisms: (1) by a direct
interaction with oestrogen receptors within the tumour cells or (2) indirectly, by reducing the supply of
oestrogens to the cells. While the supply of oestrogens can be reduced by castration in premenopausal
women, such treatment has little impact on post-menopausal oestrogens because ovarian secretion of
oestrogens ceases at the menopause (Dowsett et al., 1987; Vermeulen et al., 1976). The major pathway
of oestrogen production in post-menopausal women is by the conversion of circulating androstenedione
to oestrone by peripheral tissue (Grodin et al., 1973). In this group about 70% of circulating
androstenedione is of adrenal origin, the rest being thought to be secreted by the ovaries (Vermeulen.,
1976). Adrenalectomy and hypophysectomy were introduced nearly 40 years ago as possible treatments
of advanced breast cancer in post-menopausal patients (Huggins & Dao, 1953; Luft et al., 1952), and
although the mechanisms of action at that time were not clear, later studies confirmed that these
ablative procedures caused tumour regression in about 35% of such patients (Fracchia et al., 1971). Due
to the morbidity and mortality of such procedures the possibility of achieving similar effects by drug
treatment has been investigated. Treatment with glucocorticoids to achieve a medical suppression of
adrenal function was introduced 30 years ago (Kofman et al., 1958), but it soon become clear that the
response rates were lower than those seen following surgical adrenalectomy (Dao et al., 1961).
In 1967 aminoglutethimide, an unsuccessful antiepileptic drug which had been shown to possess
adrenal toxicity, was introduced in an attempt to provoke a more effective 'medical adrenalectomy' in
breast cancer patients (Cash et al., 1967). However, while clinical results were promising (Santen et al.,
1974), it soon became clear that this drug did not act by suppressing adrenal steroid synthesis. The
finding that plasma androstenedione levels were preserved or even increased despite a substantial fall in
plasma oestrone, suggested that aminoglutethimide might inhibit the production of oestrone from
androstenedione (Samojlik et al., 1977). This possibility was supported by the earlier observations of
Thompson & Siiteri (1974) in vitro, and in 1978 Santen and co-workers confirmed that aminoglutethi-
mide caused a 95-98% inhibition of aromatisation in post-menopausal patients with breast cancer
(Santen et al., 1978). This led to the introduction of the term 'aromatase inhibition' as a mechanism of
endocrine treatment for breast cancer.
Randomised studies have confirmed that aminoglutethimide causes response rates similar to adrena-
lectomy (Newsome et al., 1977; Santen et al., 1981) as well as to tamoxifen (Harvey et al., 1982; Lipton
et al., 1982; Smith et al., 1981). While aminoglutethimide treatment is favourable in comparison to
surgical ablative procedures in terms ofmorbidity and mortality, a certain number of side-effects such as
skin rash, ataxia and drowsiness make this drug less suited to first-line treatment than tamoxifen
(L0nning & Kvinnsland, 1988). However, since tamoxifen is being used increasingly as adjuvant therapy,
there is a need for a new first-line drug for those patients who progress to advanced disease.
Accordingly, considerable effort is being spent on developing more specific aromatase inhibitors, which
will hopefully possess fewer side effects.
One further disadvantage with aminoglutethimide is its action on enzyme systems other than the
aromatase. In the adrenals, it inhibits 20,22-desmolase, ll#-hydroxylase, 18-hydroxylase and possibly
21-hydroxylase (Cohen 1968; Dexter et al., J967; Kahnt & Neher, 1966; Sheppard et al., 1966).
Although a compensatory increase in ACTH secretion (Fishman et al., 1967) causes a sustained output
of most steroids (Harris et al., 1983; Vermeulen et al., 1983), the adrenal glucocorticoid response may be
inadequate in certain circumstances, and glucocorticoid, and sometimes mineralocorticoid, replacement
therapy are therefore recommended. Androstenedione (the one hormone for which a depression might
be beneficial) is sustained or elevated unless the patient is given concommitant glucocorticoid therapy
(Samojlik & Santen, 1978). Thus, although aminoglutethimide was at one time thought to achieve a
Received 16 February 1989. and accepted in revised form 24 February 1989.
.Cl"-- The MacmiRan Press Ltd., 1989 Br. J. Cancer (1989), 60, 5-86 P.E. L0NNING et al.
medical adrenalectomy' the overall result of the adrenal effects of aminoglutethimide is detrimental
rather than advantageous to the aim of oestrogen depression. The lack of such adrenal effects is an
important consideration in the development of new inhibitors.
In the liver, aminoglutethimide acts as an inducer of certain mixed function oxidases, causing an
increased metabolism of various substances including some drugs (L0nning et al., 1984). Recently, the
metabolic clearance rate of oestrone sulphate was also found to be increased by aminoglutethimide
(L0nning et al., 1987). This effect could be beneficial because oestrone sulphate may be an important
source of oestrogen for breast tumours, by metabolism to oestradiol within the tumour (Santner et al.,
1984). This increased metabolism may be of similar quantitative importance to the inhibition of
production in reducing the plasma levels of oestrone sulphate (L0nning et al., 1989). Thus, it seems that
aminoglutethimide may act by a dual mechanism of action: (1) aromatase inhibition and (2) suppressing
the plasma levels of oestrone sulphate by increasing its metabolism.
Although generally used in combination with hydrocortisone, the work of Stuart-Harris et al. (1984)
was valuable in demonstrating that aminoglutethimide was clinically active in the absence of adrenal
suppression. The question of the optimum dose of aminoglutethimide to use remains open. Results from
the daily use of 250mg of aminoglutethimide alone seem to be inferior to those from using the
conventional (l000mgday-1) plus hydrocortisone (Stuart-Harris et al., 1984; Murray & Pitt, 1985).
Clinical and endocrine evidence that 250mg daily with glucocorticoids is sufficient (Downsett et al.,
1985; Harris et al., 1986) require confirmation in randomised trials. One randomised trial comparing
aminoglutethimide 500mgday-1 to 1000mgday-1 revealed no significant difference in response rate
(Boneterre et al., 1985).
Testololactone is a weak androgen which was also found to be an aromatase inhibitor (Barone et al.,
1979) after its introduction as an endocrine treatment of breast cancer nearly 30 years ago (Segaloff et
al., 1960). While in vitro investigations have confirmed that this drug is a weaker aromatase inhibitor
than aminoglutethimide (Santen et al., 1982a), it causes a 90% inhibition of aromatisation in vivo
(Barone et al., 1979). This contrasts with a low clinical response rate of only 10-14% in post-menopausal
breast cancer patients (Volk et al., 1974).
Although many investigators believe aromatisation of androstenedione to oestrone may account for
most of the oestrogen production in post-menopausal women there is evidence to suggest that this may
not be the case. While aminoglutethimide will cause a near complete inhibition of the peripheral
conversion of androstenedione into oestrone, the finding of sustained plasma oestrone and oestradiol
levels at about 50% of their control values (Dowsett et al., 1985; H0ffken et al., 1986; Santen et al.,
1982b; Vermeulen et al., 1983) would seem to suggest that alternative oestrogen production pathways
exist. This is supported by isotopic tracer studies, which failed to account for total oestrogen production
from androstenedione alone (Kirschner et al., 1978; Reed et al., 1986).
The relative contribution of the different plasma oestrogens (e.g. oestrone, oestradiol, oestrone
sulphate) to intracellular tumour oestradiol is not completely understood. Neither is it clear to what
extent plasma oestrogens may account for intracellular oestrone and oestradiol levels which are more
than 10 times their plasma level in post-menopausal women (Edery et al., 1981; Fishman et al., 1977;
Millington et al., 1974; Vermeulen et al., 1986). Isotopic labelled steroid infusions have suggested that
oestrogens are concentrated inside the tumours to between 3 and 10 times the levels in plasma (McNeill
et al., 1986). A number of studies on tumour tissue in vitro have suggested that intratumoural aromatase
activity may be responsible for at least some of the intracellular oestrogen (Bezwoda et al., 1987; Lipton
et al., 1987), and one in vivo study has indicated that for some tumours such synthetic activity may be
responsible for the majority of the intratumoral oestrogen (James et al., 1988). The possibility that
oestrogens may be produced in the fat or stroma surrounding breast tumours has recently been raised
(O'Neill et al., 1988). The effect of aromatase inhibitors on this local production of oestrogens could be
an important part of their mechanism of action.
The steroid derivative 4-hydroxyandrostenedione is a potent irreversible aromatase inhibitor (Brodie
et al., 1981). There is no evidence so far to suggest that this drug inhibits other enzymes significantly
and it is as effective as aminoglutethimide in suppressing plasma oestradiol and oestrone (Dowsett et al.,
1989). Clinical trials indicate that the drug is effective at inducing clinical remission by both the
intramuscular (Goss et al., 1986), and oral routes (Cunningham et al., 1987). The response rate appears
to be similar to aminoglutethimide treatment, but this should be confirmed in further randomised
studies.
An imidazole derivative, CGS 16949A, is currently undergoing phase II trials. In vitro and in vivo
investigations have shown this drug to be a highly potent aromatase inhibitor (Schieweck et al., 1988;
Steele et al., 1988). Plasma oestrone and oestradiol levels are suppressed to a similar extent to these with
aminoglutethimide (Santen, 1988; Dowsett et al., 1988; Klepp et al., 1989). However, oestrone sulphate
is not equally suppressed (Klepp et al., 1989), possibly because CGS 16949A, unlike aminoglutethimide
does not increase the metabolic degradation of this steroid. Unfortunately, CGS 16949A does not seem
to be a totally specific aromatase inhibitor, as it has been found to suppress aldosterone levels in
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Pyridoglutethimide, a derivative of aminoglutethimide, will inhibit aromatase in vitro, but unlike
aminoglutethimide has no effect on the adrenal 20,22-desmolase (Foster et al., 1985). This drug is now
undergoing phase I trials including investigations to evaluate its effect on plasma oestrogen levels and
the secretion of adrenal steroid hormones.
With an increasing number of new aromatase inhibitors discovered in the laboratory, the importance
of selecting the right drug for clinical use will become mandatory. Currently, many patients receive
tamoxifen for adjuvant treatment, and aromatase inhibition might become first-line endocrine treatment
for advanced disease. In vitro drug potency may be a poor indicator of clinical efficacy and therapeutic
ratio. The important question is, ofcourse, whether side effects occur when a drug is administered at the
dose necessary to achieve maximal reduction in oestrogen levels.
Any difference in enzyme specificity between different drugs should be carefully considered. The need
for glucocorticoid (and sometimes mineralocorticoid) substitution in patients on aminoglutethimide is a
disadvantage; however, in skilled hands the adrenal effects of aminoglutethimide treatment do not
normally cause significant problems.
More inconvenient for many patients on aminoglutethimide treatment are the subjective side-effects
related to the CNS (drowsiness, lethargy, etc.) as well as the frequent occurrence of skin rash (L0nning
& Kvinnsland, 1988). While in most patients such side-effects will subside during the first few weeks on
treatment, in some patients they will cause long-term discomfort. The danger of serious blood dyscrasias
(in about 1% of patients on aminoglutethimide treatment) is a potential hazard caused by treatment
with this drug.
The majority of work on 4-hydroxyandrostenedione has been on the intramuscular route of
administration, and although this is undergoing a phase III trial against tamoxifen some clinicians will
consider the schedule of injections at 2-weekly intervals disadvantageous. Further work on oral
administration is needed.
While patient compliance to different aromatase inhibitors will be an important matter, two other
important and possibly related points need to be assessed: do the different aromatase inhibitors act by
identical mechanisms of action, and do they cause a similar response rate?
It is clear that testololactone and aminoglutethimide, despite a 90% and 95-98% inhibition of
peripheral aromatase respectively, do not have a similar effect on breast cancer growth. It is difficult to
believe that such a display is caus&d solely by the marginal difference in their ability to inhibit the
conversion of circulating androstenedione into oestrone. Alternatively, it is possible that this difference
may be due to a different potency of the two drugs in their action on aromatase within the tumour (or
surrounding tissue), or to alterations in plasma oestrone sulphate metabolism caused by aminoglutethi-
mide treatment. Careful studies of the effects of different aromatase inhibitors on plasma oestrogen as
well as local steriod disposition are needed to provide a rationale for further development of these
exciting drugs in the treatment of breast cancer.
P.E. L0nning is a recipient of a senior fellowship from Overlege Dr M.D. Johan Carl Unger-Vetlesen Charitable Fund.
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